Central Asset Investments & Management Holdings HK Ltd Invests $96,000 in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Central Asset Investments & Management Holdings HK Ltd bought a new stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 14,200 shares of the company’s stock, valued at approximately $96,000.

Other large investors have also recently made changes to their positions in the company. Allspring Global Investments Holdings LLC purchased a new stake in Recursion Pharmaceuticals in the third quarter valued at approximately $25,000. Decker Retirement Planning Inc. acquired a new stake in Recursion Pharmaceuticals during the 4th quarter worth $26,000. GAMMA Investing LLC grew its position in Recursion Pharmaceuticals by 1,979.2% during the 4th quarter. GAMMA Investing LLC now owns 5,198 shares of the company’s stock worth $35,000 after purchasing an additional 4,948 shares during the last quarter. Farther Finance Advisors LLC grew its position in Recursion Pharmaceuticals by 176.9% during the 3rd quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company’s stock worth $42,000 after purchasing an additional 4,091 shares during the last quarter. Finally, KBC Group NV increased its stake in Recursion Pharmaceuticals by 79.9% in the third quarter. KBC Group NV now owns 7,602 shares of the company’s stock valued at $50,000 after purchasing an additional 3,377 shares during the period. 89.06% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the stock. Needham & Company LLC reiterated a “buy” rating and set a $11.00 target price on shares of Recursion Pharmaceuticals in a research note on Thursday, February 6th. KeyCorp decreased their price objective on Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating for the company in a research report on Wednesday, January 8th.

Recursion Pharmaceuticals Stock Performance

Shares of RXRX stock opened at $8.34 on Thursday. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04. The stock has a 50 day simple moving average of $7.66 and a 200-day simple moving average of $7.06. The company has a market cap of $3.26 billion, a price-to-earnings ratio of -5.45 and a beta of 0.86. Recursion Pharmaceuticals, Inc. has a 12-month low of $5.60 and a 12-month high of $15.74.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.